[ back to News ]

Concert Pharmaceuticals to Present at the Oppenheimer 19th Annual Healthcare Conference

October 28, 2008

LEXINGTON, MA -- Concert Pharmaceuticals, Inc. announced today that it will be presenting at the Oppenheimer 19th Annual Healthcare Conference, being held at the Waldorf-Astoria Hotel in New York City. Roger Tung, Ph.D., President and Chief Executive Officer of Concert, will present an overview of the Company on Tuesday, November 4, 2008 at 8:20 a.m. (ET).

About Concert

Concert Pharmaceuticals, Inc. is a clinical stage biotechnology company dedicated to creating medically and commercially important new medicines through a novel approach utilizing the naturally-occurring element deuterium.  Concert applies its innovative platform to create highly differentiated compounds based on well-understood biological targets and drug molecules, yielding a rich pipeline of new chemical entities (NCEs).  By leveraging decades of pharmaceutical experience to design NCEs from proven therapies, Concert’s drug candidates have potential for first-in-class use in under-served medical conditions, as well as best-in-class efficacy and safety, while reducing R&D risk, time, and expense. The Company has over 100 patent applications for new drug candidates addressing a broad range of therapeutic areas, including vasomotor symptoms, HIV/AIDS and fibrotic diseases, among others.  Since its inception in 2006, Concert has raised more than $96 million and has been financed by leading venture capitalists and institutional investors.  A listing of Concert’s institutional shareholders and additional corporate information is available online at http://www.concertpharma.com.

CoNCERT and CoNCERT Pharmaceuticals are trademarks of Concert Pharmaceuticals, Inc.

[ back to top ]